AstraZeneca's KRAS deal with Yusen Jianheng; Abeona gets a PDUFA date
AstraZeneca partners with Chinese biotech: Yusen Jianheng Biopharmaceutical said last week that AstraZeneca will help develop and commercialize a preclinical small molecule that targets the KRAS G12D mutation. Per the deal, AstraZeneca will pay $24 million upfront, with milestones worth up to $395 million.
Abeona’s cell therapy granted priority review: The company announced Monday that the FDA is set to decide whether to approve prademagene zamikeracel, or pz-cel, by May 25, and the regulator does not plan to hold an advisory committee meeting. The therapy is being considered for patients with recessive dystrophic epidermolysis bullosa, a rare disease that causes the skin to blister. Its stock $ABEO was up about 13% on Monday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.